(a) y = 1.0x + 0.0; r = ; N = 60 (b) y = 1.0x + 0.0; r = ; N = Lot 1, Li-heparin whole blood, HbA1c (%)

Similar documents
COBAS, ACCU-CHECK INFORM, MODULAR and LIFE NEEDS ANSWERS are trademarks of Roche Roche

1. PROTOCOL. Comparison Study Summary. Tuality Healthcare 324 SE 9 th Ave. Suite E Hillsboro, OR July 30, 2014

1 PROTOCOL. Comparison Study Summary. Springs Memorial Hospital. Springs Memorial Hospital 800 W. Meeting St. Lancaster, SC (803)

Accuracy and Precision Performance of the Accu-Chek Mobile System. Introduction. Method

1 PROTOCOL. Comparison Study Summary

White Paper, Evaluation of WaveSense JAZZ Blood Glucose Monitoring System Analytical Performance to EN ISO 15197:2015 Standard

Aina Blood Monitoring System

Technical Bulletin. Cholesterol Reference Method Laboratory Network (CRMLN) Overview. TB Rev. 0

Polymer Technology Systems, Inc. CardioChek PA Comparison Study

Accuracy and Precision in Point-of-Care Lipid Testing: CardioChek P A Point-of-Care Test System and PTS Panels Test Strips

Commutability studies undertaken by the LNE : the case of lipid and lipoprotein testing. Vincent Delatour, PhD

College of American Pathologists (CAP) GH2 Survey Data: (updated 12/09) 2009 GH2-B (fresh pooled samples) * = NGSP certified at the time of the survey

Why do we need SD LipidoCare?

Equivalent Accuracy Evaluation of FORA Premium V10 Blood Glucose Monitoring System as Compared to Fora V30 Blood Glucose Monitoring System

510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY AND INSTRUMENT COMBINATION TEMPLATE

Electrolyte Analyzer with Ion-Selective Electrode and Blood Gas analyzer

Performance Characteristics of the Daktari CD4 System

USING THE ACCESS AMH ASSAY IN YOUR LABORATORY

Commentary by R. Little, Ph.D., NGSP Network Coordinator for the NGSP Steering Committee

System accuracy evaluation of FORA Test N Go Blood Glucose Monitoring System versus YSI 2300 STAT Plus glucose analyzer following ISO 15197:2013

Commentary by R. Little, Ph.D., NGSP Network Coordinator for the NGSP Steering Committee

SCIEX Vitamin D 200M Assay for the Topaz System

General Chemistry Scheme Guide

Evaluation Report. Eurolyser Lactate test kit (VT0220, VT0221) on solo analysers

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

System accuracy evaluation of FORA Test N Go Blood Glucose Monitoring System versus YSI 2300 STAT Plus glucose analyzer following ISO 15197:2013

Patricia C. Fallest-Strobl, 1 Elin Olafsdottir, 2 Donald A. Wiebe, 1 and James O. Westgard 1 * Lipoproteins

Evaluation Report. Eurolyser PT (INR) test kit (ST0180) on CUBE and smart analysers

The Integrated Cardiovascular Clinical Network CHSA

All-in-One Portable Lipid Analyzer

SCIENTIFIC STUDY REPORT

State of the Art of HbA1c Measurement

510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

LIPASE liquicolor. Design Verification. Multipurpose Reagent

HbA1c enzymatic assay evaluation at AN academic

1 Introduction Imprecision Within-run imprecision, results Day-to-day imprecision, results... 2

METHOD VALIDATION: WHY, HOW AND WHEN?

Customer Bulletin. Questions/Comments? Please call Customer Service at (Direct) or (Toll-free inside USA).

3 Linearity and Detection Limit Linearity Detection limit... 4

Evaluation of the LIAISON 25 OH Vitamin D TOTAL Assay on the new LIAISON XL analyser

Evaluation Report. Eurolyser HbA1c Test Kit on Smart and Cube Analyser

INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER

Evaluation Report: Eurolyser CRP test (ST0100 and ST0102) on. CUBE analyser (CA0100)

FreeStyle Lite A Blood Glucose Meter That Requires No Coding

Evaluation of Calculated Low-Density Lipoprotein Against a Direct Assay

Suppl. Table 1: CV of pooled lipoprotein fractions analysed by ESI-MS/MS

Hexagon PSA. Design Verification. Contents

IDEXX Catalyst One Chemistry Analyzer for In-house Measurement of Total Thyroxine (TT 4 ) Concentration in Serum from Dogs and Cats

Gentian Canine CRP Immunoassay Application Note for Abbott Architect * c4000

Method Comparison Report Semi-Annual 1/5/2018

For In Vitro Diagnostic Use. Rx Only. Reviewed by Date Reviewed by Date

liquicolor (AMP Buffer, IFCC) Design Verification

EQAS. Hemoglobin Program (BC80) Cycle 12: December 2014 December 2015 Sample No: 1 Sample Date: 17 Dec 14. Exceptions. Customer Information

GUIDE TO THE EVALUATION OF COMMUTABILITY OF CONTROL MATERIALS

Evaluation of Accuracy and User Performance of the TRUE METRIX Blood Glucose Monitoring System

Calibration of High-Density Lipoprotein Cholesterol Values From the Korea National Health and Nutrition Examination Survey Data, 2008 to 2015

Mipomersen (ISIS ) Page 2 of 1979 Clinical Study Report ISIS CS3

Performance Characteristics of a New Single-Sample Freezing Point Depression Osmometer

Guide to Fulfillment of Measurement Uncertainty

1,25 Dihydroxyvitamin D

Gentian Canine CRP Immunoassay Application Note for scil VitroVet*

Multicenter evaluation of the CoaguChek Prothrombin Time (PT) Test on the CoaguChek Pro II meter White paper

Clinical Accuracy and User Performance of the TRUE METRIX AIR Blood Glucose Monitoring System

Evaluation of a new hemoglobin A1c analyzer for point- of- care testing

Traceability in External Quality Assessment: How Weqas ensures traceability in EQA and stresses its importance to users. David Ducroq.

The Virtues and Pitfalls of Implementing a New Test

Accuracy of Three Dry-Chemistry Methods for Lipid Profiling and Risk Factor Classification

ClinialTrials.gov Identifier: HOE901_4020 Insulin Glargine Date: Study Code: This was a multicenter study that was conducted at 59 US sites

Selecting a Risk-Based SQC Procedure for a HbA1c Total QC Plan

Human Neurology 3-Plex A

Evaluation of Cheongmeak DCS TM Reagents for Chemistry Analyzers

The Second Report of the Expert Panel on Detection,

BÜHLMANN fcal turbo. Calprotectin turbidimetric assay for professional use. Reagent Kit B-KCAL-RSET. Revision date:

Determination of hemoglobin is one of the most commonly

Study Code: Date: 27 July 2007

cobas b 101 system Enhancing patient care at the point of need with combined HbA1c and lipid panel testing

Tina-quant Lipoprotein (a) Gen. 2 For accurate and reliable assessment of cardiovascular risk

Self-monitoring blood cholesterol (SMBC) testing: within-person day to day variation in a healthy volunteer

Diabetes, Diet and SMI: How can we make a difference?

Challenges in Performing a Scientifically Meaningful Lipemic Plasma Test in Bioanalytical Method Validation

liquicolor Design Verification

Analysis of Hemoglobin A1c from Dried Blood Spot Samples with the Tina-quant II Immunoturbidimetric Method

Evaluation of Accuracy and User Performance of the TRUE METRIX Self-Monitoring Blood Glucose System

In Vitro Diagnostic Glucose Test System

Alere Cholestech LDX Laboratory Procedure Lipid Profile GLU TC HDL GLU TC GLU Lipid Profile TC HDL TC

The analytical phase

3. System Accuracy Evaluation LUX Hgb test 1. Samples

Performance of three portable blood glucose monitoring devices used in a veterinary application

G. Snodgrass, K. Ackles, A. Blanco and A. Versaggi Ortho Clinical Diagnostics, Rochester, NY 14626

Statistical Considerations: Study Designs and Challenges in the Development and Validation of Cancer Biomarkers

IDEXX Catalyst SDMA Test for in-house measurement of SDMA concentration in serum from dogs and cats

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.

Evaluation of the Precision and Accuracy of the INRatio 2 Prothrombin Time (PT) Monitoring System

(For National Authority Use Only) Name of Study Drug: to Part of Dossier:

CRITERIA FOR USE. A GRAPHICAL EXPLANATION OF BI-VARIATE (2 VARIABLE) REGRESSION ANALYSISSys

Bringing quantitative HBsAg to the US provider, drug development and patient network

Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic

Manual. Transfer step. Figure 1. Workflow comparison of manual phenylalanine assay and automated GSP Neonatal Phenylalanine assay

Individual Lab Report Ci-Trol Nov,2016. Abnormal Fibrinogen (mg/dl) Abnormal Fbg Control - Lot# LFC Your Lab

Week 17 and 21 Comparing two assays and Measurement of Uncertainty Explain tools used to compare the performance of two assays, including

Transcription:

cobas b system - performance evaluation Study report from a multicenter evaluation of the new cobas b system for the measurement of HbAc and lipid panel Introduction The new cobas b system provides a point-of-care system for the measurement of HbAc and lipid panel (total cholesterol (TC), triglycerides (TG), high density lipoprotein cholesterol (HDL), and calculated values for low density lipoprotein cholesterol (LDL), non-hdl, and a TC/HDL ratio). The main objective of the performance evaluation was to confirm the analytical performance of the system in the hands of healthcare professionals in a point-of-care environment. Method overview The evaluation was carried out at two ISO-certified clinical laboratory sites: Barcelona, Spain and Zurich, Switzerland. The HbAc evaluation was performed from March to August, and the lipid panel from June to December,. In this evaluation, the cobas b system was evaluated using both the HbAc disc and the lipid panel disc for lot-to-lot reproducibility, precision according to CLSI EP5-A and method comparison. The cobas c 5 as a module of cobas analyzer series served as a reference system for the method comparison. Measurements were performed on the cobas b system by healthcare professionals and on the cobas c 5 module by professional laboratory technicians. Sample: The measurements were performed with various blood samples: for HbAc, capillary whole blood, venous EDTA whole blood and Li-heparin whole blood were used; for the lipid panel, capillary whole blood, venous EDTA whole blood and EDTA plasma were used. Samples were collected prospectively, and informed consent was obtained from all patients enrolled in the study. In total, 5 patients (7 male, female) were recruited with a HbAc range from. to. HbAc. patients ( male, 7 female) were recruited with lipid panel ranges: for TC from.9. mmol/l, for TG from.5.7 mmol/l and for HDL from.7. mmol/l. Quantitative assessment. All the data were analyzed using the WinCAEv tool. Statistical analysis of lot-to-lot reproducibility and method comparison data were evaluated using Passing-Bablok regression analysis. Precision experiments were analyzed by calculating the standard deviation (SD) and coefficient of variation (CV) between measurements. Qualitative assessment. Practicability and usability were qualitatively assessed by each site during the evaluation period. Key conclusions All measurements evaluated with both the HbAc disc and the lipid panel disc on the cobas b system met the pre-defined acceptance criteria for lot-to-lot reproducibility, precision and method comparison to the reference system (see Performance Evaluation Results below). The acceptance criteria for HbAc were defined according to the National Glycohemoglobin Standardization Program (NGSP) guidelines as written prior to September, as per the dates when the evaluation was carried out. Additional acceptance criteria were defined according to the Clinical and Laboratory Standards Institute (CLSI) guidelines and the National Cholesterol Education Program (NCEP) guidelines. All sites confirmed the usability and practicability of the cobas b system and rated the system as convenient for use in a point-of-care environment.

Evaluation results cobas b and HbAc disc: Lot-to-lot reproducibility Guidelines from Roche internal development were used to define the acceptance criteria for lot-to-lot reproducibility. For the concentration range of to 9 HbAc, a maximum 95 confidence interval (CI) of.5 HbAc was considered acceptable. Sample type N Mean deviation Lower 95 CI () Upper 95 CI () Acceptance criterion () Capillary WB. -.7..5 EDTA WB 7. -...5 Li-heparin WB -. -...5 Table : Lot-to-lot comparison of HbAc disc. Measurements were made on the cobas b system at the site in Barcelona. For analysis of all sample types, results obtained with Lot were used as the reference values and results from Lot as the comparator values. WB is whole blood. (a) y =.x +.; r =.99; N = (b) y =.x +.; r =.995; N = 7 (c) y =.x +.; r =.99; N = Lot, capillary whole blood, Lot, capillary whole blood, Lot, EDTA whole blood, Lot, EDTA whole blood, Lot, Li-heparin whole blood, Lot, Li-heparin whole blood, Figure a, b, c: Linear regression analysis of lot-to-lot comparison of HbAc disc. Passing-Bablok regression analysis was performed for comparison of Lot and Lot with each sample type: capillary whole blood (a), EDTA whole blood (b), and Li-heparin whole blood (c). All lot-to-lot measurements fall within the specified criteria of a 95 CI of.5 for the concentration range to 9 HbAc. For this reason, the two lots can be considered equivalent and only data from one lot will be shown for the precision and method comparison results below.

Precision Intermediate precision and repeatability of the cobas b system were measured according to CLSI EP5-A guidelines using four patient sample pools (A, B, C and D) with HbAc in four concentrations: below medical decision level (5 ), at medical decision level (.5 ), above medical decision level ( ), and significantly above medical decision level ( ). In addition, cobas b system controls covering two concentration ranges were used to assess the precision. Control level contains the concentration range. to.5 HbAc, and control level contains the concentration range 7. to. HbAc. Acceptance criteria were specified according to the CLSI guidelines for two ranges of HbAc: for HbAc 5.5, the SD should be used to assess precision, and an SD of. is specified as acceptable; for HbAc >5.5, the CV should be used to assess precision, and a CV of is specified as acceptable. Specimen Mean HbAc Intermediate SD* Intermediate CV* () Repeatability SD* Sample A 5... Sample B... Sample C...5 Sample D... Control level 5..9.7 Control level 9.9.. *according to the CLSI guidelines acceptance criteria, either SD or CV is shown. Repeatability CV* () Table : HbAc disc precision. Measurements were performed on the cobas b system over days at the site in Barcelona by using EDTA whole blood. A total of measurements were made. Table demonstrates that the precision measurements for all control samples are within the SD and CV ranges defined in the acceptance criteria. Method comparison The performance of the cobas b system with the HbAc test was compared to the cobas c 5 module with the Tina-quant HbAc Gen. reagent, which is a certified method for HbAc measurement. As a control, a reference set of eight IFCC (International Federation of Clinical Chemistry) standards was measured before and after the method comparison experiments. The statistical analysis of the correlation results were performed according to NGSP guidelines by calculating the mean deviation and the ± SD intervals (95 CI). The acceptance criteria based on these guidelines specify a 95 CI of less than.75 HbAc in the concentration range to HBAc. In addition, Passing-Bablok linear regression analysis was performed yielding the slope, intercept, and Pearson s r values for each sample type (Table, Figure a, b, c). cobas b sample type N Mean deviation Min () Max () Lower 95 CI Upper 95 CI Acceptance criterion Slope Intercept Pearson s r capillary WB..7 9. -..7.75. -..9 EDTA WB 7... -..5.75...99 Li-heparin WB.9.7 9. -.5.5.75...97 Table : Method comparison with HbAc disc. Measurements made on the cobas b system using the HbAc disc were compared with measurements made on the cobas c 5 module (reference system) at the site in Barcelona. For all cobas c 5 measurements, the sample type used was EDTA whole blood. WB is whole blood.

(a) Identity (x = y); Regression; y =.x.; r =.9; N = (b) Identity (x = y); Regression; y =.x +.; r =.99; N = 7 (c) Identity (x = y); Regression; y =.x +.; r =.97; N = cobas b, capillary whole blood, cobas c 5, EDTA whole blood, cobas b, EDTA whole blood, cobas c 5, EDTA whole blood, cobas b, Li-heparin whole blood, cobas c 5, EDTA whole blood, Figure a, b, c: Linear regression analysis of method comparison with HbAc disc. Passing-Bablok regression analysis was performed for comparison of the cobas b system against the cobas c 5 module as reference with each sample type: capillary whole blood (a), EDTA whole blood (b) and Li-heparin whole blood (c). Only EDTA whole blood was used in the cobas c 5 module for all comparisons. The acceptance criteria based on pre-september NGSP guidelines specify a 95 CI of less than.75 HbAc in the concentration range to HbAc. Table and Figures a, b and c demonstrate that the method comparison 95 CI values for the cobas b system compared to the reference cobas c 5 module fully satisfy these criteria. cobas b and lipid panel disc: Lot-to-lot reproducibility A comparison between two disc lots (Lot and Lot ) was performed for the three lipid parameters: total cholesterol (TC), triglycerides (TG), and high density lipoprotein cholesterol (HDL). Samples used for the comparison were capillary whole blood, EDTA whole blood and EDTA plasma. For each parameter, the acceptable mean bias was defined according to Roche internal development guidelines as follows: TC, ; TG, 5 ; HDL, 5. The bias was also calculated at two medically relevant decision values, referred to in Table as Bias and Bias, for each parameter as follows (TC: 5. mmol/l and.9 mmol/l; TG:.7 mmol/l and.5 mmol/l; HDL:. mmol/l and.55 mmol/l).

Sample type Test N Min Max Slope Intercept Pearson s r Mean Bias Bias Bias CV Capillary WB TC 7.....997..7.7.57 TG 9. 5.5...99.7..9.7 HDL...5 -.5.995..5.9.7 EDTA WB TC 5. 7.. -..997.5.9..57 TG. 5....9995....7 HDL 79.7..7 -.7.995.9...7 EDTA Plasma TC 9.9.. -.5.99 -. -...7 TG 9.5 5.77...999....9 HDL.7.9. -..997.9..5.57 Table : Lot-to-lot comparison of lipid panel disc. Measurements were made on the cobas b system at the site in Zurich. For analysis of all sample types, results obtained with Lot were used as the reference values and results from Lot as the comparator values. Results from Passing-Bablok regression analysis are reported (slope, intercept, Pearson s r). WB is whole blood. (a) Identity (x = y); Regression; y =.7x +.; r =.997; N = 7 (b) Identity (x = y); Regression; y =.5x +.; r =.99; N = 9 (c) Identity (x = y); Regression; y =.x -.5; r =.995; N = 9 Lot, capillary whole blood, TC 7 5 5 7 9 Lot, capillary whole blood, TC Lot, capillary whole blood, TG 5 5 Lot, capillary whole blood, TG Lot, capillary whole blood, HDL Lot, capillary whole blood, HDL Figure a, b, c: Linear regression analysis of lot-to-lot comparison of lipid panel disc. Passing-Bablok regression analysis was performed for comparison of Lot and Lot with capillary whole blood for each lipid parameter: TC(a), TG (b), and HDL (c). In Figure a, b and c, regression graphs are shown for the capillary blood samples only. Refer to Table for results from EDTA whole blood and EDTA plasma (graphs available upon request). All mean biases for the lot-to-lot measurements fall within the specified criteria for each parameter: TC, ; TG, 5 ; HDL, 5. For this reason, the two lots can be considered equivalent and only data from one lot will be shown for the precision and method comparison results below.

Precision Intermediate precision and repeatability of the cobas b system were evaluated according to CLSI EP5-A guidelines using two control samples covering both normal and pathological concentration ranges for all three lipid parameters. Acceptance criteria were specified according to the CLSI guidelines for two ranges of each parameter. For TC with a concentration of. mmol/l, the criteria is an SD.9 mmol/l; for concentration >. mmol/l, the criteria is CV. For TG with a concentration of.7 mmol/l, the criteria is an SD.9 mmol/l; for concentration >.7 mmol/l, the criteria is CV 5. For HDL with a concentration of.9 mmol/l, the criteria is an SD. mmol/l; for concentration >.9 mmol/l, the criteria is CV. Sample Test Min Max Mean Intermediate precision SD* Intermediate precision CV* () Repeatability SD* Repeatability CV* () Control Level Control Level TC.59.9... TG.7.5... HDL.99...5. TC.9 7. 7... TG..57.9..7 HDL..7.77.5. *according to the CLSI guidelines acceptance criteria, either SD or CV is shown. Table 5: Lipid panel disc precision. Measurements were performed on the cobas b system over days at the Zurich site using standard control samples with two concentration ranges. A total of measurements were made. All units are in mmol/l, unless otherwise indicated. Table 5 demonstrates that the intermediate precision and repeatability measurements for both of the control sample levels fall within the SD or CV ranges defined, satisfying the acceptance criteria. Method comparison The performance of the cobas b system with the lipid panel test was compared to the cobas c 5 module for TC, TG, and HDL measurement. As a control, measurements were performed with NIST (National Institute of Standards and Technology) standards (two different concentration levels for TC and TG, no material for HDL was available) before and after the method comparison experiments. Both prospective and residual patient samples were used in the experiments. The acceptance criteria were defined according to the NCEP and CDC (Cholesterol Disease Control) guidelines and are summarized in Table. Statistical analysis of the correlation results was performed according to the NCEP guidelines including calculation of the mean deviation over all measurements, the bias at two medically relevant decision values (TC: 5. mmol/l and.9 mmol/l; TG:.7 mmol/l and.5 mmol/l; HDL:. mmol/l and.55 mmol/l), and the total error (TE). Calculation of the TE was performed as follows: TE () = Mean Bias () +.9 x CV (). In addition, Passing-Bablok regression analysis was performed yielding the slope, intercept, and Pearson s r values for each sample type (Table 7, Figure a, b, c).

Parameter/Test Mean Bias Bias Bias TE TC <.9 TG 5 5 5 <5 HDL 5 5 5 < Table : Summary of acceptance criteria for method comparison of lipid panel disc. cobas b sample type Test N Min Max Slope Intercept Pearson s r Mean Bias Bias Bias CV TE Capillary WB TC. 7.7. -..99 -.5 -.5...7 TG.5.57...999..5..9. HDL 7.7.7.9..97...7..57 EDTA WB TC 9. 7.7. -..99 -.9 -.9 -..55. TG 7.5.57...997..... HDL.7..9..9 -.5. -.5..9 EDTA Plasma TC.9.. -..99 -.5 -. -..5.7 TG 9.5.77.99..999 -.7 -. -.7.. HDL 5.9..9..97 -.5 -. -..7.75 Table 7: Method comparison with lipid panel disc. Measurements made on the cobas b system using the lipid panel disc were compared with the measurements made on the cobas c 5 module (reference system) at the site in Barcelona. For all measurements on the cobas c 5, the sample type was Li-heparin plasma. WB is whole blood. (a) Identity (x = y); Regression; y =.9x -.75; r =.99; N = (b) Identity (x = y); Regression; y =.x +.; r =.999; N = (c) Identity (x = y); Regression; y =.9x +.5; r =.97; N = 7 9 Lot, cobas b, capillary whole blood, TC 7 5 5 7 9 cobas c 5, Li-heparin plasma, TC Lot, cobas b, capillary whole blood, TG 5 5 cobas c 5, Li-heparin plasma, TG Lot, cobas b, capillary whole blood, HDL..5..5..5.5..5..5. cobas c 5, Li-heparin plasma, HDL Figure a, b, c: Linear regression analysis of method comparison with lipid panel disc. Passing-Bablok regression analysis was performed for comparison of the cobas b system versus the cobas c 5 module as reference with capillary whole blood for the three lipid parameters: TC (a), TG (b) and HDL (c). Li-heparin plasma was used on the cobas c 5 module for all comparisons. Table 7 demonstrates that the method comparison mean bias, the bias at the two medically relevant decision values and the total error satisfy the acceptance criteria determined according to the NCEP and CDC guidelines as specified in Table.

COBAS, COBAS B, COBAS C and LIFE NEEDS ANSWERS are trademarks of Roche. Roche Roche Diagnostics International Ltd CH- Rotkreuz Switzerland www.cobas.com